Quantcast

Latest Mycophenolic acid Stories

2010-08-26 07:00:00

EXTON, Pa., Aug. 26 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrends®: Kidney Transplantation report. This report is based on online survey results from over 150 physicians (general nephrologists, transplant nephrologists and transplant surgeons). It provides an in-depth view of the kidney transplantation market, including the roles of the various specialties, promotional efforts and sales representative messaging, barriers to kidney...

2010-08-09 07:00:00

WALTHAM, Mass., Aug. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor...

2010-07-08 08:00:00

EXTON, Pa., July 8 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends(®): Systemic Lupus Erythematosus (SLE). This report provides a comprehensive market overview of current and future treatment trends in SLE based on a primary research study fielded with 102 rheumatologists in the U.S. in June. The difficulty in treating the complex, relapsing and remitting course of SLE is manifested in rheumatologists'...

2009-08-12 18:35:00

DEERFIELD, Ill., Aug. 12 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today an update regarding the status of the request for emergency relief and preliminary injunction from the U.S. Food and Drug Administration's (FDA) decision regarding its Citizen Petition. The company's requests have been denied by the U.S. District Court in Washington, D.C. The company is disappointed in the court's decision and is currently evaluating its next course of action. The Citizen...

2009-08-11 07:00:00

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry and uptake of premium-priced biologics will drive the systemic lupus erythematosus drug market to more than quadruple from approximately $420 million in 2008 to nearly $2 billion in 2018. The new Pharmacor report entitled Systemic Lupus Erythematosus finds that the primary drivers of market growth will be the entry...

2009-08-10 22:52:00

DEERFIELD, Ill., Aug. 10 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has substantially denied the company's Citizen Petition to ensure the safe and effective use of immunosuppressants (also called anti-rejection medications) used to prevent rejection in organ transplant patients. In their petition, Astellas requested that the FDA take additional measures to protect transplant recipients, a unique and vulnerable...

2009-08-04 14:00:00

Underweight and very severely obese patients at riskA recent study by doctors at the University of Washington explained that patients who are significantly underweight or very severely obese prior to liver transplantation are at increased risk of death following transplantation surgery. These findings, from the largest known observation of liver transplantation at the extremes of BMI, are published in the August issue of Liver Transplantation, a journal published by John Wiley & Sons on...

2009-07-14 12:00:57

The U.S. Food and Drug Administration is ordering manufacturers of some immunosuppressant drugs used in kidney transplants to change their labeling. The FDA said the updated labels must reflect an increased risk of infections. The required label changes affect drugs used to help prevent rejection of transplanted organs. The drugs are Rapamune (sirolimus), Sandimmune (cyclosporine), and three generic drugs, Neoral (cyclosporine modified), Cellcept (mycophenolate mofetil) and Myfortic...

2009-05-28 08:00:00

DEERFIELD, Ill., May 28 /PRNewswire/ -- The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf(R) (tacrolimus) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients. Prograf is a cornerstone therapy for preventing transplant rejection in liver, kidney and heart transplant recipients. The approval came on May 19, 2009 in response to a Supplemental New Drug Application (sNDA)...

2009-05-07 07:00:00

PITTSBURGH, May 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Mycophenolate Mofetil Tablets, 500 mg, and Mycophenolate Mofetil Capsules, 250 mg. Mycophenolate Mofetil is the generic name for Roche's CellCept(R), which is indicated for the prevention of organ rejection in patients receiving...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.